Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Global Select Requirement for Nasdaq Minimum Bid Price Requirement

Rhea-AI Summary

Trinity Biotech (Nasdaq: TRIB) received a Nasdaq notice on Feb 11, 2026 that it is not in compliance with Nasdaq Listing Rule 5450(a)(1) because its ADS closing bid price fell below $1.00 for the prior 30 consecutive business days.

The ADSs continue to trade on the Nasdaq Global Select Market. The company has 180 calendar days, until Aug 10, 2026, to regain compliance by achieving a $1.00 closing bid for at least 10 consecutive business days. If not cured, eligibility for a second compliance period requires meeting the MVPHS $15,000,000 and other listing standards for The Nasdaq Capital Market. Management is evaluating options to cure the deficiency and maintain listing.

Positive

• ADSs continue trading on Nasdaq Global Select
• 180-day cure period ending Aug 10, 2026
• Eligibility for second compliance if MVPHS $15,000,000 met

Negative

• Non-compliance with Nasdaq Rule 5450(a)(1) due to sub-$1.00 bid
• Must achieve $1.00 closing bid for 10 consecutive business days by Aug 10, 2026
• Potential transfer to Nasdaq Capital Market or delisting if deficiency not cured

Key Figures

Nasdaq minimum bid: $1.00 per share Non-compliance period: 30 consecutive business days Compliance window: 180 calendar days +5 more

8 metrics

Nasdaq minimum bid $1.00 per share Nasdaq Listing Rule 5450(a)(1) requirement

Non-compliance period 30 consecutive business days Closing bid below $1.00 for ADSs

Compliance window 180 calendar days Period to regain Nasdaq minimum bid compliance

Compliance deadline August 10, 2026 End of initial compliance period

Required bid streak 10 consecutive business days Minimum time closing bid must be ≥ $1.00

MVPHS threshold $15,000,000 Minimum value of publicly held shares for possible extension

Current price $0.77 Pre-notice trading level vs $1.00 Nasdaq requirement

52-week range $0.48 – $3.44 Positioned 77.62% below 52-week high

Market Reality Check

Price: $0.7700 Vol: Today’s volume 94,043 vs ...

low vol

$0.7700 Last Close

Volume Today’s volume 94,043 vs 20-day average 325,249 (relative volume 0.29x), indicating subdued trading interest into this notice. low

Technical Price at $0.77 is trading below the $0.92 200-day moving average and far under the $3.44 52-week high.

Peers on Argus

TRIB is down 4.62% while peer moves are mixed: IRIX (-1.43%), NSYS (+3.81%), ADG...

1 Down

TRIB is down 4.62% while peer moves are mixed: IRIX (-1.43%), NSYS (+3.81%), ADGM (-9.78%), AIMD (-1.91%), PTHL (+113.16%). Only one momentum-scanner peer (NMTC -1.99%) moved in the same direction, suggesting a stock-specific reaction to the compliance notice.

Historical Context

5 past events · Latest: Feb 10 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 10	Regulatory clearance	Positive	+8.8%	Approval to begin offshored upstream manufacturing for Uni‑Gold HIV test.
Feb 10	Product recognition	Positive	+8.8%	Premier Hb9210 HbA1c analyser received exclusive IFCC Gold Classification for 2026.
Dec 23	Financing agreements	Positive	+43.5%	Perceptive credit agreements adding term loan and equitization capacity, extending maturity.
Dec 23	Major order & results	Positive	+43.5%	9M-unit TrinScreen HIV order plus strong Q3 2025 revenue and margin metrics.
Dec 15	Product rollout	Positive	-12.2%	Expanded rollout of high-capacity HbA1c column system after regulatory clearances.

Pattern Detected

Recent operational and financing news has often led to positive price reactions, though at least one strong operational update saw a negative move, indicating occasional divergence.

Recent Company History

Over the past few months, Trinity Biotech reported several regulatory and commercial milestones. On Dec 23, 2025, new capital structure agreements and a major TrinScreen HIV order coincided with +43.5% moves. Earlier, expanded HbA1c rollout in more than 10 countries saw a -12.15% reaction despite positive framing. On Feb 10, 2026, IFCC Gold Classification for its Premier Hb9210 analyser and regulatory approval for offshored Uni‑Gold HIV manufacturing were followed by +8.75% moves. Today’s Nasdaq minimum bid-price notice contrasts with those growth-oriented updates.

Market Pulse Summary

This announcement centers on TRIB’s failure to meet Nasdaq’s $1.00 minimum bid price for 30 consecut...

Analysis

This announcement centers on TRIB’s failure to meet Nasdaq’s $1.00 minimum bid price for 30 consecutive business days, triggering a formal 180-day cure period ending August 10, 2026. Management plans to monitor the ADS bid and evaluate options to regain compliance, while trading continues on the Nasdaq Global Select Market. In light of recent operational milestones and financing steps, investors may track progress toward the 10-day bid-price requirement and the company’s ability to satisfy any conditions for additional compliance periods.

Key Terms

nasdaq global select market, american depositary shares, nasdaq listing rule 5450(a)(1), minimum bid price

4 terms

nasdaq global select market regulatory

"continue to trade at this time on the Nasdaq Global Select Market under the symbol"

A Nasdaq Global Select Market listing is the highest tier of stocks on the Nasdaq exchange, reserved for companies that meet the strictest financial, reporting and governance standards. For investors, it acts like a premium quality label—signaling larger, more transparent and better-governed companies that tend to offer greater liquidity and lower perceived risk compared with lower-tier listings, making it easier to buy, sell and evaluate shares.

american depositary shares financial

"the Company’s American Depositary Shares (“ADSs”) for the last 30 consecutive"

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

nasdaq listing rule 5450(a)(1) regulatory

"not in compliance with Nasdaq Listing Rule 5450(a)(1), requiring that listed"

Nasdaq Listing Rule 5450(a)(1) is a continued-listing standard that sets a minimum share price companies must maintain to remain listed on the Nasdaq market—commonly a $1.00 per-share threshold. Investors care because falling below that floor can trigger a compliance review and possible delisting, which is like failing a minimum grade and losing access to the public market; delisting can reduce liquidity, visibility and the ability to raise capital.

minimum bid price financial

"requiring that listed securities maintain a minimum bid price of $1.00 per share"

The minimum bid price is the lowest share price that a market, regulator, or specific offering will accept for a trade, listing, or auction—think of it as a reserve or floor that a stock must meet to qualify for certain actions. It matters to investors because falling below that floor can limit trading options, trigger compliance measures or delisting risks, and affect liquidity and the perceived value of a holding, much like a reserve price in an auction sets the baseline for a sale.

AI-generated analysis. Not financial advice.

DUBLIN, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, received notice on February 11, 2026 from the Nasdaq Stock Market LLC (“Nasdaq”) that the Company is not in compliance with Nasdaq Listing Rule 5450(a)(1), requiring that listed securities maintain a minimum bid price of $1.00 per share, based on the closing bid price of the Company’s American Depositary Shares (“ADSs”) for the last 30 consecutive business days.

This notice has no immediate effect on the listing of the Company’s ADSs, which will continue to trade at this time on the Nasdaq Global Select Market under the symbol “TRIB.”

In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has a period of 180 calendar days, or until August 10, 2026, to regain compliance with the minimum bid price requirement. To regain compliance, the closing bid price of the Company’s ADSs must meet or exceed $1.00 for at least ten consecutive business days during this 180-calendar day period. In the event the Company does not regain compliance, the Company may be eligible for additional time if it meets the continued listing requirement for minimum value of publicly held shares (“MVPHS”) ($15,000,000) and all other initial listing standards for The Nasdaq Capital Market, with the exception of the bid price and provides written notice to Nasdaq of its intention to cure the deficiency during the second compliance period.

Management intends to actively monitor the bid price for its ADSs and to cure the deficiency within the prescribed grace period. During this time, the Company expects that the ADSs of the Company will continue to be listed and trade on the Nasdaq Global Select Market. The Company’s management is evaluating various options available to regain compliance and maintain its continued listing.

Forward-Looking Statements
This release includes statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Reform Act”), including but not limited to statements related to Trinity Biotech’s cash position, financial resources and potential for future growth, market acceptance and penetration of new or planned product offerings, and future recurring revenues and results of operations. Trinity Biotech claims the protection of the safe harbor for forward-looking statements contained in the Reform Act. These forward-looking statements are often characterized by the terms “may,” “believes,” “projects,” “expects,” “anticipates,” or words of similar import, and do not reflect historical facts. Specific forward-looking statements contained in this release may be affected by risks and uncertainties, including, but not limited to, our ability to capitalize on the Waveform transaction and of our recent acquisitions, our continued listing on the Nasdaq Stock Market, our ability to achieve profitable operations in the future, our ability to reduce our debt and improve our capitalization, the impact of the spread of COVID-19 and its variants, the possible pause and/or disruption in U.S. Government funding for HIV tests produced by Trinity Biotech, potential excess inventory levels and inventory imbalances at the company’s distributors, losses or system failures with respect to Trinity Biotech’s facilities or manufacturing operations, the effect of exchange rate fluctuations on international operations, fluctuations in quarterly operating results, dependence on suppliers, the market acceptance of Trinity Biotech’s products and services, the continuing development of its products, required government approvals, risks associated with manufacturing and distributing its products on a commercial scale free of defects, risks related to the introduction of new instruments manufactured by third parties, risks associated with competing in the human diagnostic market, risks related to the protection of Trinity Biotech’s intellectual property or claims of infringement of intellectual property asserted by third parties and risks related to condition of the United States economy and other risks detailed under “Risk Factors” in Trinity Biotech’s annual report on Form 20-F for the fiscal year ended December 31, 2024 and Trinity Biotech’s other periodic reports filed from time to time with the United States Securities and Exchange Commission. Forward-looking statements speak only as of the date the statements were made. Trinity Biotech does not undertake and specifically disclaims any obligation to update any forward-looking statements.

About Trinity Biotech

Trinity Biotech is a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors. The Company develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market and has recently entered the wearable biosensor industry, with the acquisition of the biosensor assets of Waveform Technologies Inc. and intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. Our products are used to detect infectious diseases and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States and through a network of international distributors and strategic partners in over 75 countries worldwide. For further information, please see the Company's website: www.trinitybiotech.com.

Contact:	Trinity Biotech plc Paul Murphy (353)-1-2769800	RedChip Companies Inc. Dave Gentry, CEO (1)-407-644-4256 (1)-800-RED-CHIP (733-2447) TRIB@redchip.com

FAQ

What did Trinity Biotech (TRIB) notify investors about on Feb 11, 2026?

The company said it received a Nasdaq notice for non-compliance with the $1.00 minimum bid. According to the company, this followed 30 consecutive business days with closing bids below $1.00, triggering the Nasdaq cure period.

How long does Trinity Biotech (TRIB) have to regain Nasdaq compliance?

Trinity Biotech has a 180-calendar-day cure period to regain compliance, ending Aug 10, 2026. According to the company, the period allows time to raise the ADS closing bid to $1.00 for 10 consecutive business days.

What price and duration must TRIB reach to meet Nasdaq minimum bid requirements?

TRIB must achieve a $1.00 closing bid for at least 10 consecutive business days within the 180-day period. According to the company, meeting that threshold restores compliance under Nasdaq rules.

Will TRIB shares stop trading after the Nasdaq notice?

No, the ADSs are expected to continue trading on Nasdaq Global Select at this time. According to the company, the notice does not have an immediate effect on the listing while the cure period runs.

What happens if Trinity Biotech (TRIB) fails to regain compliance by Aug 10, 2026?

If TRIB fails to cure, it may be eligible for a second compliance period only if it meets the MVPHS $15,000,000 and other listing standards. According to the company, written notice to Nasdaq is required to seek that relief.

What actions is Trinity Biotech (TRIB) taking to address the Nasdaq deficiency?

Management says it is actively monitoring the ADS bid price and evaluating options to cure the deficiency. According to the company, efforts are underway to regain compliance within the prescribed grace period.